Citi analyst Patrick Donnelly keeps a Buy rating on Danaher (DHR) with a $265 price target and placed the shares on a “90-day positive catalyst watch.” While the backdrop for tools remains variable, Citi is more constructive on Danaher, the analyst tells investors in a research note. The firm sees the company’s bioprocessing guidance of 6%-7% for Q1 as conservative and views its recent cost-out initiatives positively in diagnostics and in China.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DHR:
- Unusually active option classes on open February 26th
- Early notable gainers among liquid option names on February 21st
- Danaher: Strategic Cost Savings Initiative and Resilient Management Underpin Buy Rating
- Danaher: Cost-Saving Initiatives and Growth Potential Amidst Stock Pressure
- Danaher Appoints Charles W. Lamanna to Board